Japan Delegation Concludes Visit to North Carolina to Explore Life Sciences Partnerships
Organized by the Japan External Trade Organization (JETRO) and co-organized by the Economic Development Partnership of North Carolina (EDPNC), the Research Triangle Regional Partnership, Greater Winston-Salem, Inc., and the Charlotte Regional Business Alliance, the visit included tours of key facilities within North Carolina's thriving life sciences ecosystem.
The delegation commenced its visit with a meeting with Governor Josh Stein, followed by a tour of the North Carolina Plant Sciences Building at North Carolina State University and the Biomanufacturing Training and Education Center (BTEC), where they explored academic–industry collaboration in workforce development. The group also visited Spark LS, a 109-acre advanced life science campus, FUJIFILM Diosynth Biotechnologies, and Astellas Gene Therapies.
On the second day, the delegation visited the Innovation Quarter in Winston-Salem and toured the Wake Forest Institute for Regenerative Medicine (WFIRM) to gain insights into cutting-edge initiatives in regenerative medicine. Additional site visits included Winston Starts, Ricoh, Mercodia, and Charter Medical. The day concluded with a warm welcome from Mayor Allen Joines.
On the final day, the delegation visited the North Carolina Research Campus in Kannapolis and toured the North Carolina Food Innovation Lab. They also visited Coddle Creek Capital and the University of North Carolina Nutrition Research Institute. The visit concluded at The Pearl, Charlotte's emerging hub for healthcare innovation and scientific advancement.
JETRO looks forward to deepening its collaboration with the State of North Carolina, building on the growing momentum between Japan and the region in advanced technology sectors.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
an hour ago
- Associated Press
R&D Investments Fuel Next-Gen Immunomodulator Development Amid Patent Expiry
DUBLIN--(BUSINESS WIRE)--Jul 4, 2025-- The 'Immunomodulator Therapeutics Market, Global, 2024-2030" report has been added to offering. Revenue estimate for the base year 2024 is $93 billion with a CAGR of 9.0% for the study period 2024-2030. This research service offers a comprehensive analysis of the global immunomodulator therapeutics market, specifically targeting inflammatory disorders in the immunology, gastrointestinal (GI), and dermatology segments. The report defines this market through products designed to modify and regulate pathological immune responses, either by inhibiting or suppressing them. It categorizes the market by modality and key indications, providing a 6-year revenue forecast for global immunomodulator prescription drugs, alongside an analysis of key industry participants. The geographic scope encompasses North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and Latin America (LATAM), with regional revenue share estimates presented on a best-effort basis. The report also discusses prevalent and emerging business models, analyzes trends in market access and reimbursement for immunomodulator therapies, and offers competitive assessments and revenue share analyses. It examines the factors driving and restraining growth in this space, offering insights into drug development trends, partnerships, and the investment landscape. The report highlights key companies pioneering disruptive virtual care technologies and adjunctive therapies for effective disease management. Based on clinical needs, technological advancements, business models, and competitive dynamics, the report identifies the growth opportunities emerging from this space for market players and stakeholders to leverage. The base year is 2024, and the forecast period is from 2025 to 2030. Growth Drivers Rising Prevalence of Autoimmune and Inflammatory Diseases Increasing prevalence of diseases like lupus, RA, Crohn's disease, and psoriasis is driving demand for immunomodulators like tumor necrosis factor (TNF) inhibitors (e.g., Humira, Remicade) and JAK inhibitors (e.g., Xeljanz). The rapidly aging global population is more susceptible to chronic autoimmune conditions. It is further bolstering demand for treatments tailored to older adults, such as more tolerable biologics. Biotech Advancements Innovations in biotech platforms and advanced modalities such as CGT, bispecific antibodies, and RNA therapies are enhancing the efficacy and safety profiles of immunomodulators and driving the development of next-gen targeted therapies. Carisma Therapeutics Inc. and Moderna, Inc. have collaborated to use Carisma's proprietary CAR-M technology and Moderna's mRNA/lipid nanoparticles (LNP) platform to develop a macrophage engineering approach for autoimmune diseases. Growing Investment in R&D Increased funding from both public and private sectors is accelerating R&D efforts for discovering new therapies and improving existing ones. The NIH allocates significant funding for research on immunomodulatory therapies, fostering innovation. An increasing number of M&A deals demonstrate a growing focus on immunology by big pharma. Success in Oncology and Expanding Applications The success of immunotherapies in oncology has raised awareness and acceptance of similar approaches in treating autoimmune and inflammatory diseases. For example, Roche's Gazyva/Gazyvaro (obinutuzumab), approved in 100 nations for several lymphoma types, is being investigated in the Phase III REGISTRY trial for lupus nephritis. Growth Restraints Immunomodulator Therapeutics: Growth Restraints, Global, 2025-2030 Stringent Regulatory Processes: Stringent regulatory processes for immunomodulatory treatment approval or the development of novel mechanisms of action, globally, can cause delays in market access and raise development expenses for pharmaceutical companies. Moreover, inadequate reimbursement/insurance coverage globally may deter wide-scale adoption, especially in public health systems or regions with limited healthcare resources. Inadequate coverage of high-cost new drugs would increase the expenses of managing long-term conditions, impacting patient compliance and market growth. Potential Adverse Effects and Safety Concerns: Immunomodulators may have serious adverse effects, such as an elevated risk of infections and autoimmune responses. For example, checkpoint inhibitor use in autoimmune disease is linked to immune-related side effects that need to be carefully managed. Adverse outcomes and safety risks may lead to regulatory actions such as market recalls, limited prescriptions, and reduced patient confidence, challenging market uptake. Patent Expiry: Expiry of blockbuster drug patents is leading to the introduction of biosimilars and generic versions, intensifying market competition, resulting in price erosions, and leading to a loss of sales revenue for branded products. For example, AbbVie's blockbuster Humira, approved for several autoimmune conditions like RA, psoriasis, Crohn's disease, and ankylosing spondylitis, started facing biosimilar competition in 2023. Patient Inconvenience: Biotech advancements have facilitated the development of effective biologic therapies; however, therapy administration requires frequent injections or infusions, making it challenging for patients to adhere to their treatment regimens. It may affect overall patient satisfaction and treatment discontinuation. The Impact of the Top 3 Strategic Imperatives on the Immunomodulator Therapeutics Industry Disruptive Technologies Why: There is an increasing incidence of autoimmune diseases, particularly impacting women. Limitations in existing therapies demand more targeted applications. Analyst Perspective: A new wave of drug classes (JAK1, IL, calcineurin, TNF?, TYK2, PDE4), across small molecules, biologics, and cell and gene therapies, will emerge, offering enhanced efficacy and safety profiles for treating autoimmune and inflammatory conditions. There will be a growing trend towards combination therapies that utilize multiple mechanisms of action to achieve better clinical outcomes. Internal Challenges Why: The industry is moving toward an extended patent cliff, with several revenue-generating blockbuster drugs like Humira and Stelara losing their exclusivity, leading to revenue losses and increased biosimilar competition, creating an urgent need for pipeline growth, and driving increased research and development (R&D). Resource demands for R&D can strain budgets, especially for smaller biotech firms. Analyst Perspective: Companies may increasingly seek strategic partnerships to share costs and risks, fostering innovation through collaborative R&D efforts. Companies that emphasize unique value propositions in these strategic alliances will be better positioned to access markets/fair pricing with drugs like JAK inhibitors and women-specific therapies. Payers will scrutinize clinical costs and patient outcomes to ensure balance and sustainable reimbursement models that reflect indication-specific needs and improve affordability. Transformative Megatrends Why: Healthcare systems are under pressure to contain current and future spending. Healthcare plan sponsors are considering their next moves as governments contemplate the impact of the Inflation Reduction Act (IRA) 2022, and associated price cuts in the United States. Analyst Perspective: Firms will invest in adaptive trial designs for evidence generation to expedite approvals for novel MoA-based targeted therapies, advancing precision medicine going forward. Pharma companies will utilize diagnostic delivery services to improve patient access by partnering with telehealth/AI-enabled symptom monitoring platforms (e.g., Ada Health) and focus on an emerging market-expansion strategy. Focus on predictive convergence of drugs and digital therapeutics will likely personalize medicine and improve experiences and outcomes. Scope of Analysis Ecosystem in the Immunomodulator Therapeutics Sector Growth Opportunity Universe in Immunomodulator Therapeutics Sector Key Competitors For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. View source version on CONTACT: Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 KEYWORD: INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH SOURCE: Research and Markets Copyright Business Wire 2025. PUB: 07/04/2025 06:43 AM/DISC: 07/04/2025 06:43 AM
Business Wire
3 hours ago
- Business Wire
Tikehau Capital: Disclosure of Shares Repurchases from 27 June 2025 to 03 July 2025
PARIS--(BUSINESS WIRE)--Regulatory News: In accordance with Article 5 of EU Regulation n° 596/2014 (Market Abuse Regulation), detailed information is available on the website of Tikehau Capital (Paris:TKO):
Business Wire
3 hours ago
- Business Wire
SCENTMATIC's AI "KAORIUM" Debuts at THAMEEN Fragrance Launch in London's Selfridges
LONDON--(BUSINESS WIRE)--SCENTMATIC Inc., a leader in scent digitalization, introduced its AI-powered scent-to-language system, KAORIUM, at the THAMEEN Fragrance new product launch event. This pivotal event took place from June 5 to 11, 2025, at Selfridges department store in London, UK. Global Expansion: KAORIUM Establishes UK Presence Europe leads the global fragrance market, with the UK projected to reach US$2.82 billion by 2033. Recognizing this, SCENTMATIC is rapidly expanding its international footprint. In May 2024, SCENTMATIC established its overseas subsidiary, KAORIUM, in London, appointing industry expert Ben Yanoushek as CEO. Official UK operations commenced on February 1, 2025, with the launch of its dedicated website: KAORIUM Trialed at "Florentine Diamond" Launch Event The "Florentine Diamond" launch event for luxury brand THAMEEN Fragrance served as the initial trial for KAORIUM. Held in a prestigious section of Selfridges' beauty hall, the event attracted many visitors. On the opening day, a special breakfast event for industry professionals and influencers at Selfridges' "Brasserie of Light" allowed guests to experience KAORIUM firsthand through individual sessions. SCENTMATIC remains dedicated to showcasing KAORIUM's innovative ability to blend scent and language, enhancing sensory experiences both domestically and internationally. About THAMEEN Fragrance THAMEEN, a UK-based niche fragrance brand, translates to "precious" in Arabic. Inspired by rare jewels, it crafts exquisite, long-lasting Extrait de Parfums using carefully selected, high-quality ingredients. What is "KAORIUM"? KAORIUM is SCENTMATIC's AI system that mutually translates between scent and language. It visualizes elusive scent impressions with words and identifies scents linked to specific words. This unique experience activates both brain hemispheres, unlocking new sensitivities. KAORIUM's potential spans fragrance, education, dining, and purchasing, creating diverse business opportunities. SCENTMATIC Inc. Established in 2019, SCENTMATIC is a business design collective focused on "digitalizing olfaction." Through scent and language, it aims to evolve human sensibility and innovate various industries by adding emotional value to experiences. Representative: Toshiharu Kurisu Representative Director Location: 3F, 4-22-7 Ebisu, Shibuya-ku, Tokyo 150-0013, Japan URL:
